{"abstract":"The Food and Drug Administration (FDA, the Agency, or we) is proposing to amend certain prescription drug marketing regulations to reflect changes to affected provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) resulting from enactment of the Drug Supply Chain Security Act (DSCSA), Title II of the Drug Quality and Security Act (DQSA). This action, if finalized, will remove or revise outdated and conflicting regulatory requirements to align with changes to affected provisions of the FD&C Act following enactment of the DSCSA.","action":"Proposed rule.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2022/02/04/2022-01927.html","cfr_references":[{"chapter":null,"citation_url":null,"part":"203","title":21}],"citation":"87 FR 6443","comment_url":null,"comments_close_on":"2022-04-05","correction_of":null,"corrections":[],"dates":"Submit either electronic or written comments on the proposed rule by April 5, 2022.","disposition_notes":null,"docket_ids":["Docket No. FDA-2020-N-1819"],"dockets":[{"supporting_documents":[{"title":"Ref 1 - Economic Analysis RE Certain Requirements Regarding Prescription Drug Marketing","document_id":"FDA-2020-N-1819-0008"}],"agency_name":"FDA","documents":[{"comment_count":6,"comment_start_date":"2022-02-04","updated_at":"2023-02-28T12:29:11.222-05:00","comment_url":"https://www.regulations.gov/commenton/FDA-2020-N-1819-0001","allow_late_comments":null,"id":"FDA-2020-N-1819-0001","comment_end_date":"2022-04-06","regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":1,"id":"FDA-2020-N-1819","title":"Certain Requirements Regarding Prescription Drug Marketing; Proposed Rule."}],"document_number":"2022-01927","effective_on":null,"end_page":6449,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2022/02/04/2022-01927.xml","html_url":"https://www.federalregister.gov/documents/2022/02/04/2022-01927/certain-requirements-regarding-prescription-drug-marketing","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2022-01927?publication_date=2022-02-04","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2022-02-04/2022-01927/mods.xml","not_received_for_publication":null,"page_length":7,"page_views":{"count":2487,"last_updated":"2026-10-23 02:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-02-04/pdf/2022-01927.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-01927.pdf?1643895914","publication_date":"2022-02-04","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2022/02/04/2022-01927.txt","regulation_id_number_info":{"0910-AH56":{"issue":"202110","html_url":"https://www.federalregister.gov/regulations/0910-AH56/certain-requirements-regarding-prescription-drug-marketing-203-amendment-","title":"Certain Requirements Regarding Prescription Drug Marketing (203 Amendment)","xml_url":"http://www.reginfo.gov/public/do/eAgendaViewRule?pubId=202110&RIN=0910-AH56&operation=OPERATION_EXPORT_XML","priority_category":"Substantive, Nonsignificant"}},"regulation_id_numbers":["0910-AH56"],"regulations_dot_gov_info":{"supporting_documents":[{"title":"Ref 1 - Economic Analysis RE Certain Requirements Regarding Prescription Drug Marketing","document_id":"FDA-2020-N-1819-0008"}],"comments_count":6,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2020-N-1819","supporting_documents_count":1,"docket_id":"FDA-2020-N-1819","document_id":"FDA-2020-N-1819-0001","regulation_id_number":null,"title":"Certain Requirements Regarding Prescription Drug Marketing; Proposed Rule.","checked_regulationsdotgov_at":"2023-02-28T17:29:10Z"},"regulations_dot_gov_url":null,"significant":false,"signing_date":null,"start_page":6443,"subtype":null,"title":"Certain Requirements Regarding Prescription Drug Marketing","toc_doc":"Certain Requirements Regarding Prescription Drug Marketing","toc_subject":null,"topics":["Labeling","Prescription drugs","Reporting and recordkeeping requirements","Warehouses"],"type":"Proposed Rule","volume":87}